# US 2026/0102412 A1 · Polycannabinoids, compounds, compositions and methods of use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0102412 A1
- Document ID: US20260102412A1
- Status: Published application
- Kind: A1
- Application number: 19/235,244
- Filed: 2025-06-11
- Published: 2026-04-16
- Earliest claimed: 2020-04-17
- Assignees: University of Connecticut
- Applicants: University of Connecticut
- Inventors: Gregory Allen Sotzing
- Web page: https://patentgrep.com/patent/US20260102412A1

## CPC

- A61K 31/658: {o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol}
- A61K 31/765: Polymers containing oxygen
- A61K 9/1635: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/7007: {Drug-containing films, membranes or sheets (A61K9/0041, A61K9/0043, A61K9/006, A61K9/0063 take precedence)}
- A61K 9/7023: {Transdermal patches and similar drug-containing composite devices, e.g. cataplasms (galenical aspects of iontophoretic devices A61K9/0009; microneedle arrays A61K9/0021; buccal patches A61K9/006)}
- A61K 47/32: Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers {, poly(meth)acrylates, or polyvinyl pyrrolidone}
- A61K 47/55: the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
- A61L 29/06: obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
- A61L 29/085: {Macromolecular materials}
- A61L 29/16: Biologically active materials, e.g. therapeutic substances {(A61L29/048 takes precedence)}
- A61L 31/06: obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds {(A61L31/041 takes precedence)}
- A61L 31/16: Biologically active materials, e.g. therapeutic substances {(A61L31/047 takes precedence)}
- C08F 32/00: Homopolymers and copolymers of cyclic compounds having no unsaturated aliphatic radicals in a side chain, and having one or more carbon-to-carbon double bonds in a carbocyclic ring system
- C08F 36/20: unconjugated
- C08F 36/22: the radical having three or more carbon-to-carbon double bonds
- C08G 63/21: in the presence of unsaturated monocarboxylic acids or unsaturated monohydric alcohols or reactive derivatives thereof
- C08G 63/547: Hydroxy compounds containing aromatic rings
- A61L 2300/216: with other specific functional groups, e.g. aldehydes, ketones, phenols, quaternary phosphonium groups
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- C08F: MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08G: MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS

## Abstract

Polymers comprising a plurality of cannabinoids, methods of preparation thereof, and methods of use to treat a number of disease conditions are reported. Also provided are polymer coatings, films, fibers, and non-woven fabrics for a variety of topical applications including stents, bandages, sutures, and transdermal patches.

## Claims

### Claim 1

A polymer that comprises a plurality of cannabinoid units wherein the polymer has the formula:
wherein:
CNB is a CNB cannabinoid unit,
L is a linking group; and
n represents the number of repeat units wherein n is at least 2;
wherein the polymer further comprises one or more endcapping groups, wherein the one or more endcapping groups are selected from a cannabinoid unit having one hydroxyl group, an acid group, or an ester group before reaction with the polymer.

### Claim 2 (depends on 1)

The polymer according to claim 1, wherein each CNB cannabinoid unit is independently derived from: CBG, CBD, CBC, CBND, dihydro-DHCBD, CBG-V, CBD-V, CBC-V, CBND-V, or dihydro-DHCBD-V, and
wherein each CNB cannabinoid unit is bound to the linking group via hydroxyl groups, acid groups, or ester groups on the CNB cannabinoid unit before polymerization.

### Claim 3 (depends on 1)

The polymer according to claim 1, wherein each CNB cannabinoid unit has one of the following structures before polymerization:
and
wherein the R group is: C1-C10 alkyl optionally substituted with one or more heteroatoms, a heterocycloalkyl group, or a heteroaryl group; specifically methyl, ethyl, propyl, butyl, pentyl, hexyl, 4′-(3-carboxypropyl)-, 4′-(4-hydroxybutyl), 1,1-dimethylheptyl, 4′-[2-(1H-1,2,3-triazol-yl)ethyl]-, 4′-(2-morpholinoethyl)-, or 4′-(2-ethoxyethyl)-.

### Claim 4 (depends on 1)

The polymer according to claim 1, wherein the CNB cannabinoid units comprise structurally identical cannabinoid units.

### Claim 5 (depends on 1)

The polymer according to claim 1, wherein the CNB cannabinoid units comprise structurally different cannabinoid units.

### Claim 6 (depends on 1)

The polymer according to claim 1, wherein the one or more endcapping groups have the following structure before reaction with the polymer:

### Claim 7 (depends on 1)

The polymer according to claim 1, wherein the linking group is a linear or branched hydrocarbon chain containing from 3 to 50 carbon atoms,
optionally interrupted with one or more oxygen atoms, aromatic groups, or benzyl groups, or
optionally substituted with hydrophilic groups.

### Claim 8 (depends on 7)

The polymer according to claim 7, wherein the hydrocarbon chain contains from 3 and 8 carbon atoms.

### Claim 9 (depends on 1)

The polymer according to claim 1, wherein the linking group is a monomer which polymerizes to form a vinyl polymer, a polyurethane, a polyester, a polyether, a polyamide, a polyimide, a polyamino acid, a polypeptide, a polysaccharide, or a combination thereof.

### Claim 10 (depends on 1)

The polymer according to claim 1, wherein the linking group is of the general formula —O—(CH2—CHOR1—CH2)m—O—, wherein each R1 individually denotes a hydrogen atom or a —CH2—CHOH—CH2—O— chain bound to a CNB cannabinoid unit of the polymer.

### Claim 11 (depends on 9)

The polymer according to claim 9, wherein the vinyl monomer is a (meth)acrylic monomer, a styrene monomer, a (meth)acrylamide monomer, an ethylene monomer, a propylene monomer, an oxyethylene monomer, an ethylene glycol monomer, a propylene glycol monomer, a monomer of vinyl alcohol, a vinyl acetate monomer, or a vinyl chloride monomer.

### Claim 12 (depends on 9)

The polymer according to claim 9, wherein the vinyl monomer is a (meth)acrylic acid or a salt thereof, a (meth)acrylic acid ester, methyl (meth)acrylate, ethyl (meth)acrylate, hydroxymethyl (meth)acrylate, hydroxyethyl (meth)acrylate, styrene, a styrene sulfonate, a (meth)acrylamide, dimethyl (meth)acrylamide, diethyl (meth)acrylamide, N-isopropylacrylamide, or N-benzylacrylamide.

### Claim 13 (depends on 1)

The polymer according to claim 1, wherein the number average molecular weight is about 1,000 daltons to about 60,000 daltons.

### Claim 14 (depends on 1)

The polymer according to claim 1, wherein the average molecular weight is about 15,000 daltons to about 50,000 daltons.

### Claim 15 (depends on 1)

The polymer according to claim 1, wherein the polymer comprises a temperature for onset of thermal degradation of greater than 300 degrees Celsius when measured by non-isothermal TGA.

### Claim 16 (depends on 1)

The polymer according to claim 1, wherein the polymer is a linear polymer.

### Claim 17 (depends on 1)

The polymer according to claim 1, wherein the polymer is a branched polymer.

### Claim 18 (depends on 1)

A pharmaceutical composition comprising the polymer according to claim 1 and a pharmaceutically acceptable carrier.

### Claim 19 (depends on 1)

A cosmetic composition comprising the polymer according to claim 1 and a cosmetically acceptable carrier.

### Claim 20 (depends on 1)

An article comprising the polymer according to claim 1, wherein the article is a microsphere, a film, a fiber, a fiber matrix, a nonwoven fabric, a woven fabric, a wound dressing, a medical device, a stent, a catheter, a catheter coating, or a transdermal patch.

### Claim 21

A method for delivering a cannabinoid to a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a polymer that comprises a plurality of cannabinoid units wherein the polymer has the formula:
wherein:
CNB is a CNB cannabinoid unit,
L is a linking group; and
n represents the number of repeat units wherein n is at least 2;
wherein the linking group comprises a di- or tri-carboxylic acid linking group comprising citric acid, fumaric acid, glutamic acid, maleic acid, malic acid, malonic acid, oxalic acid, succinic acid, glutaric acid, terephthalic acid, isophthalic acid, oxaloacetic acid, phthalic acid, adipic acid, or butanedioic acid, and wherein the polymer further comprises one or more endcapping groups, wherein the one or more endcapping groups are selected from a cannabinoid unit having one hydroxyl group, an acid group, or an ester group before reaction with the polymer.

### Claim 22 (depends on 21)

The method according to claim 21, wherein each CNB cannabinoid unit is independently derived from: CBG, CBD, CBC, CBND, dihydro-DHCBD, CBG-V, CBD-V, CBC-V, CBND-V, or dihydro-DHCBD-V, and
wherein each CNB cannabinoid unit is bound to the linking group via hydroxyl groups, acid groups, or ester groups on the CNB cannabinoid unit before polymerization.

### Claim 23 (depends on 21)

The method according to claim 21, wherein each CNB cannabinoid unit has one of the following structures before polymerization:
and
wherein the R group is: C1-C10 alkyl optionally substituted with one or more heteroatoms, a heterocycloalkyl group, or a heteroaryl group; specifically methyl, ethyl, propyl, butyl, pentyl, hexyl, 4′-(3-carboxypropyl)-, 4′-(4-hydroxybutyl), 1,1-dimethylheptyl, 4′-[2-(1H-1,2,3-triazol-yl)ethyl]-, 4′-(2-morpholinoethyl)-, or 4′-(2-ethoxyethyl)-.
